How does dietary carbohydrate influence the formation of an atherogenic lipoprotein phenotype?

Submission date Recruitment status Prospectively registered 19/05/2010 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 19/05/2010 Completed [X] Results [] Individual participant data Last Edited Condition category Nutritional, Metabolic, Endocrine 23/05/2022

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Bruce Griffin

Contact details

Faculty of Health and Medical Science Guildford United Kingdom GU2 7XH

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

NCT01790984

Protocol serial number

6517

Study information

Scientific Title

How does dietary carbohydrate influence the formation of an atherogenic lipoprotein phenotype?

Acronym

DRN 270 Carbohydrate and Lipoproteins

Study objectives

Despite the falling trend in death from cardiovascular disease (CVD) in the UK in the last 10 years, the morbidity in CVD is increasing exponentially as a direct result of the cardio-metabolic risk arising from obesity, metabolic syndrome and type 2 diabetes. One of the key public health nutritional strategies to prevent this from happening is to replace dietary fat, principally saturated fat, with carbohydrate, to reduce such risk factors as serum low density lipoprotein (LDL) cholesterol. However, meta-analyses have firmly established that replacing dietary fat with carbohydrate is not associated with a decrease in CVD risk. Moreover, when the amount and quality of carbohydrate is uncontrolled, an exchange of fat for carbohydrate can increase risk arising from the insulin-resistant conditions described above. Recent evidence suggests that this adverse effect of dietary carbohydrate on CVD risk can be ameliorated by controlling the quality of carbohydrate; this may be achieved by limiting intake of non-milk extrinsic sugars (fructose and sucrose) and increasing non-starch polysaccharides (NCP).

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved, ref: 08/H1109/227

Study design

Single-centre randomised interventional process of care trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Diabetes Research Network, Primary Care Research Network for England; Subtopic:

Other; Disease: Cardiovascular disease

Interventions

The study will be a randomised, dietary intervention with a cross-over design. It will examine the effect of two test diets for 12 weeks, that differ in the quality of carbohydrate (high and low non-milk extrinsic sugars [NMES]), in two groups of subjects at risk of metabolic syndrome but with different proportions of liver fat (low liver fat less than 2% and moderate liver fat greater than 10% but less than 20%). The test diets will be preceded by a 4-week run-in diet and separated by 4 weeks of wash-out.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Formation of high- and low-risk lipoprotein phenotypes

Key secondary outcome(s))

- 1. LDL kinetics, with a focus on the formation of small dense LDL
- 2. Sources of liver fat
- 3. Whether VLDL-TG is derived from increased DNL and/or systemically derived NEFA
- 4. VLDL kinetics, with focus on differential effects on the synthesis of VLDL-TG and VLDL-apoB

Completion date

01/09/2011

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/2009

Date of final enrolment

01/09/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Faculty of Health and Medical Science

Guildford United Kingdom GU2 7XH

Sponsor information

Organisation

Biotechnology and Biological Sciences Research Council (BBSRC) (UK)

ROR

https://ror.org/00cwqg982

Funder(s)

Funder type

Research council

Funder Name

Biotechnology and Biological Sciences Research Council (BBSRC) (UK)

Alternative Name(s)

UKRI - Biotechnology And Biological Sciences Research Council, BBSRC UK, Biotechnology and Biological Sciences Research Council (BBSRC), BBSRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Basic results27/05/202123/05/2022NoNo